To print: Select File and then Print from your browser's menu

Title: Metastatic Breast Cancer Patients With Poor Performance Status Respond Well to Ixabepilone Plus Capecitabine: Presented at SABCS

"Metastatic Breast Cancer Patients With Poor Performance Status Respond Well to Ixabepilone Plus Capecitabine: Presented at SABCS"

By Charlene Laino SAN ANTONIO, Tex -- December 15, 2008 -- For patients with metastatic breast cancer who have poor performance status and who show resistance to anthracyclines and taxanes, ixabepilone plus capecitabine improves overall survival, progression-free survival, and tumour response compared with capecitabine alone, according to results of 2 large phase 3 studies, presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS). Symptomatic metastatic breast cancer patients with poor performance status pose a difficult therapeutic challenge, due to a worse prognosis and greater risk of toxicity from chemotherapy than patients with good performance status, stated PierFranco Conte, MD, University Hospital, Modena, Italy, speaking at a poster presentation here on December 14. Dr. Conte and colleagues theorised that ixabepilone -- the first in a new class of antineoplastic agents -- plus capecitabine would offer a new option for such patients. The combination showed consistent clinical benefit compared with capecitabine alone in 2 large clinical trials of patients with metastatic breast cancer who had tumours resistant to anthracycline and a taxane (Thomas ES et al. [J Clin Oncol. 2007;25:3399-3406) or pretreated with anthracycline and a taxane (Hortobagyi GN et al. 44th Annual Meeting of the American Society of Clinical Oncology [ASCO] 2008 Breast Cancer Symposium. Abstract 186).

The researchers sought to better evaluate treatment effect in the subset of patients with a Karnofsky performance status of 70 to 80 by performing a predefined pooled analysis of findings from both the Thomas and Hortobagyi studies.

Both studies had a similar design. A total of 1,973 patients with metastatic breast cancer who were previously treated with an anthracycline and a taxane were randomised to receive ixabepilone (40 mg/m² IV over 3 hours, every 3 weeks) plus oral capecitabine (1,000 mg/m² twice a day for 14 days, every 3 weeks) or oral capecitabine alone (1,250 mg/m² twice a day for 14 days, every 3 weeks). A total of 606 (31%) patients in the 2 studies had a Karnofsky performance status of 70 to 80; of these, 314 received combination treatment and 292 received capecitabine alone.

Outcome data on progression-free survival, overall survival, and tumour response were available for 268 patients in the combination arm and 257 patients in the capecitabine monotherapy arm. The median progression-free survival time was 4.6 months in the combination arm compared with 3.1 months in the capecitabine monotherapy arm. This finding corresponded to a 24% reduction in progression-free survival in the capecitabine arm (P = .0021).

The median overall survival time was 12.3 months in the ixabepilone plus capecitabine arm versus 9.5 months in the capecitabine monotherapy arm. This finding corresponded to a 25% reduction in overall survival in the monotherapy arm (P = .0015).

The overall response rate was 36% in the combination arm versus 19% in the capecitabine monotherapy arm. Specifically, in the combination arm, 2% of patients had a complete response, 34% had a partial response, and another 40% had stable disease. In the capecitabine monotherapy arm, there were no complete responders, and 19% of patients showed a partial response; another 37% of patients had stable disease.

There was an increased incidence of adverse events, primarily neutropenia and peripheral neuropathy, associated with combination versus monotherapy, Dr. Conte said. Seventy-one percent of 310 patients in the combination arm for whom safety data were available developed grade 3/4 neutropenia compared with 11% of the 288 patients in the capecitabine monotherapy arm. Twenty-three percent of patients in the combination arm developed peripheral neuropathy compared with 1% in the monotherapy arm.

Dr. Conte noted that the adverse events were generally manageable by dose reduction or interruption.

"Ixabepilone plus capecitabine provides a new treatment option for symptomatic patients where the standard of care is single-agent sequential therapy," Dr. Conte concluded.

Funding for this study was provided by Bristol-Myers Squibb Company.

[Presentation title: Ixabepilone Plus Capecitabine Improves Overall Survival in Symptomatic Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane in 2 Large Phase III Studies. Abstract 6114]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.